Core Viewpoint - BGM Group's stock price increased by 7.53% to $8.00 per share, with a market capitalization of $1.472 billion as of August 13 [1] Financial Performance - As of March 31, 2025, BGM Group reported total revenue of $14.3114 million, representing a year-on-year growth of 13.92% [1] - The net profit attributable to the parent company was -$0.8612 million, showing a significant decrease of 307.79% year-on-year [1] Company Overview - BGM Group, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] - Tetracycline raw materials are used for producing human antibiotics and support global poultry and aquaculture industries [1] - Crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]

Core Insights - BGM's stock price increased by 4.63% to $8.025 per share, with a total market capitalization of $1.476 billion as of August 9 [1] - For the fiscal year ending March 31, 2025, BGM reported total revenue of $14.3114 million, reflecting a year-on-year growth of 13.92%, while net profit attributable to shareholders was a loss of $0.8612 million, a significant decrease of 307.79% compared to the previous year [1] Company Overview - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] - Tetracycline raw materials are used not only for human antibiotics but also support the global aquaculture and livestock industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, which are key anticoagulants [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]

8月7日，博美集团(BGM)开盘上涨9.28%，截至21:33，报8.95美元/股，成交2255.0美元，总市值16.46亿 美元。 本文源自：金融界 作者：行情君 财务数据显示，截至2025年03月31日，博美集团收入总额1431.14万美元，同比增长13.92%；归母净利 润-86.12万美元，同比减少307.79%。 资料显示，博美集团有限公司前身为祁连国际控股集团有限公司,总部位于中国成都,是一家专注于生物 制药、生物萃取、医疗健康领域的创新型企业。公司目前的产品范围包括土霉素原料药,甘草制剂和粗 肝素钠。土环素原料药不仅为制药公司生产人用抗生素提供原料,也为全球养殖业和畜牧业提供支持,确 保家禽和海产品的安全。粗肝素钠经下游企业加工后,转化为精制肝素钠和注射肝素钠溶液,是主要的抗 凝血剂。甘草制剂,如复方甘草含片,用作止咳药并供应给零售药店。 ...

8月6日，博美集团(BGM)盘中上涨2.77%，截至23:18，报8.16美元/股，成交5.09万美元，总市值15.01亿 美元。 财务数据显示，截至2025年03月31日，博美集团收入总额1431.14万美元，同比增长13.92%；归母净利 润-86.12万美元，同比减少307.79%。 资料显示，博美集团有限公司前身为祁连国际控股集团有限公司,总部位于中国成都,是一家专注于生物 制药、生物萃取、医疗健康领域的创新型企业。公司目前的产品范围包括土霉素原料药,甘草制剂和粗 肝素钠。土环素原料药不仅为制药公司生产人用抗生素提供原料,也为全球养殖业和畜牧业提供支持,确 保家禽和海产品的安全。粗肝素钠经下游企业加工后,转化为精制肝素钠和注射肝素钠溶液,是主要的抗 凝血剂。甘草制剂,如复方甘草含片,用作止咳药并供应给零售药店。 本文源自：金融界 作者：行情君 ...

资料显示，博美集团有限公司前身为祁连国际控股集团有限公司,总部位于中国成都,是一家专注于生物 制药、生物萃取、医疗健康领域的创新型企业。公司目前的产品范围包括土霉素原料药,甘草制剂和粗 肝素钠。土环素原料药不仅为制药公司生产人用抗生素提供原料,也为全球养殖业和畜牧业提供支持,确 保家禽和海产品的安全。粗肝素钠经下游企业加工后,转化为精制肝素钠和注射肝素钠溶液,是主要的抗 凝血剂。甘草制剂,如复方甘草含片,用作止咳药并供应给零售药店。 本文源自：金融界 作者：行情君 8月6日，博美集团(BGM)盘中上涨8.06%，截至21:45，报8.58美元/股，成交2582.0美元，总市值15.78亿 美元。 财务数据显示，截至2025年03月31日，博美集团收入总额1431.14万美元，同比增长13.92%；归母净利 润-86.12万美元，同比减少307.79%。 ...

8月4日，博美集团(BGM)盘中上涨6.16%，截至22:00，报9.13美元/股，成交2.78万美元，总市值16.80亿 美元。 财务数据显示，截至2025年03月31日，博美集团收入总额1431.14万美元，同比增长13.92%；归母净利 润-86.12万美元，同比减少307.79%。 资料显示，博美集团有限公司前身为祁连国际控股集团有限公司,总部位于中国成都,是一家专注于生物 制药、生物萃取、医疗健康领域的创新型企业。公司目前的产品范围包括土霉素原料药,甘草制剂和粗 肝素钠。土环素原料药不仅为制药公司生产人用抗生素提供原料,也为全球养殖业和畜牧业提供支持,确 保家禽和海产品的安全。粗肝素钠经下游企业加工后,转化为精制肝素钠和注射肝素钠溶液,是主要的抗 凝血剂。甘草制剂,如复方甘草含片,用作止咳药并供应给零售药店。 本文源自：金融界 作者：行情君 ...

Financial Performance - As of March 31, 2025, the company's total revenue reached $14.31 million, representing a year-over-year increase of 13.92% [1] - The net profit attributable to the parent company was -$0.8612 million, showing a significant decrease of 307.79% compared to the previous year [1] Company Overview - The company, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] Product Applications - Tetracycline raw materials are used not only for producing human antibiotics but also support the global aquaculture and livestock industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, which are major anticoagulants [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]

资料显示，博美集团有限公司前身为祁连国际控股集团有限公司,总部位于中国成都,是一家专注于生物 制药、生物萃取、医疗健康领域的创新型企业。公司目前的产品范围包括土霉素原料药,甘草制剂和粗 肝素钠。土环素原料药不仅为制药公司生产人用抗生素提供原料,也为全球养殖业和畜牧业提供支持,确 保家禽和海产品的安全。粗肝素钠经下游企业加工后,转化为精制肝素钠和注射肝素钠溶液,是主要的抗 凝血剂。甘草制剂,如复方甘草含片,用作止咳药并供应给零售药店。 本文源自：金融界 作者：行情君 7月31日，博美集团(BGM)开盘上涨6.71%，截至21:30，报9.625美元/股，成交1.95万美元，总市值17.71 亿美元。 财务数据显示，截至2025年03月31日，博美集团收入总额1431.14万美元，同比增长13.92%；归母净利 润-86.12万美元，同比减少307.79%。 ...

Group 1 - The stock price of BGM increased by 5.37% to $9.81 per share, with a total market capitalization of $1.805 billion as of July 31 [1] - For the fiscal year ending March 31, 2025, BGM reported total revenue of $14.3114 million, representing a year-over-year growth of 13.92%, while the net profit attributable to shareholders was a loss of $0.8612 million, a decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on innovative solutions in the biopharmaceutical, biorefining, and healthcare sectors [1] Group 2 - The company's product range includes raw materials for oxytetracycline, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and the global livestock industry [1] - Oxytetracycline raw materials are used to produce human antibiotics and support the safety of poultry and seafood in the livestock sector [1] - Crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant, while licorice preparations, such as compound licorice tablets, are used as cough remedies supplied to retail pharmacies [1]

本文源自：金融界 作者：行情君 7月30日，博美集团(BGM)盘中上涨3.05%，截至21:44，报9.594美元/股，成交9781.0美元，总市值17.65 亿美元。 财务数据显示，截至2025年03月31日，博美集团收入总额1431.14万美元，同比增长13.92%；归母净利 润-86.12万美元，同比减少307.79%。 资料显示，博美集团有限公司前身为祁连国际控股集团有限公司,总部位于中国成都,是一家专注于生物 制药、生物萃取、医疗健康领域的创新型企业。公司目前的产品范围包括土霉素原料药,甘草制剂和粗 肝素钠。土环素原料药不仅为制药公司生产人用抗生素提供原料,也为全球养殖业和畜牧业提供支持,确 保家禽和海产品的安全。粗肝素钠经下游企业加工后,转化为精制肝素钠和注射肝素钠溶液,是主要的抗 凝血剂。甘草制剂,如复方甘草含片,用作止咳药并供应给零售药店。 ...